Background Overactivation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome can lead to severe illness in patients with coronavirus disease-2019 (COVID-19). The NLRP3 inhibitor, colchicine, therefore, appears to be promising for the treatment of COVID-19. Aims We aimed to perform a meta-analysis of randomized trials investigating the effect of colchicine in patients with COVID-19. Materials & Methods We systematically searched electronic databases and clinical trial registries (up to October 17, 2021) for eligible studies. The outcomes of interest were all-cause mortality and duration of hospital stay. Meta-analysis with the random-effects model was used to estimate the pooled odds ratio (OR) of mortality and 95% confidence interval (CI). The pooled standardized mean difference of duration of hospital stay with 95% CI between colchicine users and non-colchicine users was estimated using Cohen's d index. Results The meta-analyses revealed no significant difference in the odds of mortality (pooled OR = 0.76; 95% CI: 0.53–1.07), but a significant reduction in the duration of hospital stay with the use of colchicine (pooled standardized mean difference = −0.59; 95% CI: −1.06 to −0.13).Discussion and Conclusion The ability of colchicine to reduce the length of stay in hospitalized patients with COVID-19 is consistent with its potential to prevent clinical deterioration via inhibition of NLRP3 inflammasome. Nevertheless, such beneficial effects of colchicine did not translate into mortality benefits in patients with COVID-19.
|Number of pages||10|
|Journal||Immunity, inflammation and disease|
|Early online date||30 Dec 2021|
|Publication status||Published - 1 Feb 2022|